Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.49 CAD | +1.36% | +4.20% | -16.76% |
Apr. 11 | Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA | CI |
Apr. 11 | Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA | MT |
Sales 2024 * | 857K 627K | Sales 2025 * | 6.68M 4.89M | Capitalization | 111M 81.14M |
---|---|---|---|---|---|
Net income 2024 * | -36M -26.35M | Net income 2025 * | -40M -29.28M | EV / Sales 2024 * | 129 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 16.6 x |
P/E ratio 2024 * |
-3.36
x | P/E ratio 2025 * |
-3.39
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.84% |
Latest transcript on Oncolytics Biotech Inc.
1 day | +1.36% | ||
1 week | +4.20% | ||
Current month | +2.76% | ||
1 month | +6.43% | ||
3 months | -12.35% | ||
6 months | -29.72% | ||
Current year | -16.76% |
Managers | Title | Age | Since |
---|---|---|---|
Matthew Coffey
CEO | Chief Executive Officer | - | 11-05-10 |
Kirk Look
DFI | Director of Finance/CFO | - | 03-03-31 |
Thomas Heineman
CTO | Chief Tech/Sci/R&D Officer | - | 20-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jonathan Rigby
BRD | Director/Board Member | 56 | 22-09-06 |
Patricia Andrews
BRD | Director/Board Member | 66 | Jan. 08 |
Bernd Seizinger
BRD | Director/Board Member | 67 | 15-06-07 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 1.49 | +1.36% | 62,335 |
24-04-24 | 1.47 | +2.80% | 29,418 |
24-04-23 | 1.43 | -2.05% | 22,910 |
24-04-22 | 1.46 | +1.39% | 34,851 |
24-04-19 | 1.44 | +0.70% | 23,577 |
Delayed Quote Toronto S.E., April 25, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.76% | 80.79M | |
+1.12% | 43.84B | |
+6.77% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.01% | 25.53B | |
-24.92% | 18.18B | |
-3.63% | 12.29B | |
+27.16% | 12.29B | |
+7.30% | 11.15B |
- Stock Market
- Equities
- ONC Stock